Assessment of the safety and probiotic properties of Roseburia intestinalis: A potential “Next Generation Probiotic”

Abstract

Roseburia intestinalis is an anaerobic bacterium that produces butyric acid and belongs to the phylum Firmicutes. There is increasing evidence that this bacterium has positive effects on several diseases, including inflammatory bowel disease, atherosclerosis, alcoholic fatty liver, colorectal cancer, and metabolic syndrome, making it a potential “Next Generation Probiotic.” We investigated the genomic characteristics, probiotic properties, cytotoxicity, oral toxicity, colonization characteristics of the bacterium, and its effect on the gut microbiota. The genome contains few genes encoding virulence factors, three clustered regularly interspaced short palindromic repeat (CRISPR) sequences, two Cas genes, no toxic biogenic amine synthesis genes, and several essential amino acid and vitamin synthesis genes. Seven prophages and 41 genomic islands were predicted. In addition to a bacteriocin (Zoocin A), the bacterium encodes four metabolic gene clusters that synthesize short-chain fatty acids and 222 carbohydrate-active enzyme modules. This bacterium is sensitive to antibiotics specified by the European Food Safety Authority, does not exhibit hemolytic or gelatinase activity, and exhibits some acid resistance. R. intestinalis adheres to intestinal epithelial cells and inhibits the invasion of certain pathogens. In vitro experiments showed that the bacterium was not cytotoxic. R. intestinalis did not affect the diversity or abundance of the gut flora. Using the fluorescent labelling method, we discovered that R. intestinalis colonizes the cecum and mucus of the colon. An oral toxicity study did not reveal any obvious adverse effects. The lethal dose (LD)50 of R. intestinalis exceeded 1.9 × 109 colony forming units (CFU)/kg, whereas the no observed adverse effect level (NOAEL) derived from this study was 1.32 × 109 CFU/kg/day for 28 days. The current research shows that, R. intestinalis is a suitable next-generation probiotic considering its probiotic properties and safety.

Sterile faecal filtrate transplantation alters phage-microbe dynamics in individuals with metabolic syndrome: a double blind, randomised, placebo-controlled clinical trial assessing efficacy and safety

“…Looking at the bacterial hosts of these phages, we found 10 host species that were significantly enriched, of which 9 were more prevalent in the FFT group. One of these bacterial hosts is the butyrate producer Roseburia intestinalis , which has been found to be depleted in MetSyn 38,39 and contributes to inflammatory signalling inhibition and intestinal barrier repair 40,41 . Another short-chain fatty acid producer belonging to the Eisenbergiella species has been associated with increased skeletal muscle mass 42 .…”

Acetolactate Decarboxylase as an Important Regulator of Intracellular Acidification, Morphological Features, and Antagonism Properties in the Probiotic Lactobacillus reuteri

“…Whereas auto‐aggregation is a significant essential for the constitution of biofilm, which further assists adhesion and colonization of host epithelial cells of the intestinal tract by probiotics. [ 45 ] Co‐aggregation, on the other hand, qualifies probiotics to form obstacles that are efficient in the prevention of intestinal pathogen adhesion to gut cells. [ 45 ] The co‐aggregation ability also depends on the pathogen tested; the WT and ΔaldB detected show co‐aggregation abilities for all tested pathogens (Figure 5C).…”

“…Auto‐aggregation, co‐aggregation, and CSH ability were identified based on the method described by Zhang et al., [ 45 ] and Boya et al., [ 46 ] with slight modifications, respectively. The strains WT and ΔaldB were rinsed three times and resuspended in PBS.…”

Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy?

“…Pediococcus acidilactici UAMS, as a high butyrate-producing bacterium, was isolated from bhaati jaanr and inhibited the proliferation of HT29 and SW480 (113). Roseburia intestinalis, Faecalibacterium prausnitzii, Lactiplantibacillus plantarum, and Eubacterium callanderi have also been proven to enhance the anti-cancer immune response in CRC accompanied by butyrate production (114)(115)(116)(117). Lactic acid-producing bacteria played a major role in controlling intestinal carcinogenesis because of SCFAs synthesis (118).…”